QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:SGMO

Sangamo Therapeutics - SGMO Stock Forecast, Price & News

$1.76
-0.14 (-7.37%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.73
$1.94
50-Day Range
$1.90
$3.67
52-Week Range
$1.73
$6.42
Volume
2.23 million shs
Average Volume
1.62 million shs
Market Capitalization
$296.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.83

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
686.0% Upside
$13.83 Price Target
Short Interest
Bearish
9.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Sangamo Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.29) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

291st out of 986 stocks

Biological Products, Except Diagnostic Industry

46th out of 165 stocks


SGMO stock logo

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
What 4 Analyst Ratings Have To Say About Sangamo Therapeutics
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Earnings Preview For Sangamo Therapeutics
Here's Why Sangamo (SGMO) Looks Ripe for Bottom Fishing
Wedbush Keeps Their Hold Rating on Sangamo Biosciences (SGMO)
Sangamo Therapeutics's Earnings Outlook
Sangamo Therapeutics (NASDAQ: SGMO)
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Company Calendar

Last Earnings
2/22/2023
Today
3/22/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
431
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$13.83
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+686.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-192,280,000.00
Net Margins
-172.76%
Pretax Margin
-172.37%

Debt

Sales & Book Value

Annual Sales
$111.30 million
Book Value
$1.80 per share

Miscellaneous

Free Float
164,102,000
Market Cap
$296.52 million
Optionable
Optionable
Beta
1.17

Social Links


Key Executives

  • Alexander D. Macrae
    President, Chief Executive Officer & Director
  • Mark D. McClung
    Chief Operating Officer & Executive Vice President
  • Prathyusha Durabaibu
    Senior VP, Chief Financial & Accounting Officer
  • R. Andrew Ramelmeier
    Executive Vice President-Technical Operations
  • Jason D. Fontenot
    Chief Scientific Officer & Senior Vice President













SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price forecast for 2023?

6 analysts have issued 12 month price targets for Sangamo Therapeutics' stock. Their SGMO share price forecasts range from $5.00 to $19.00. On average, they anticipate the company's stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 686.0% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2023?

Sangamo Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, SGMO shares have decreased by 43.9% and is now trading at $1.76.
View the best growth stocks for 2023 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company earned $27.23 million during the quarter, compared to analyst estimates of $26.86 million. Sangamo Therapeutics had a negative net margin of 172.76% and a negative trailing twelve-month return on equity of 61.19%. Sangamo Therapeutics's revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) EPS.

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Credit Suisse AG (2.32%), Dimensional Fund Advisors LP (2.10%), Avidity Partners Management LP (1.68%), Geode Capital Management LLC (1.52%), Renaissance Technologies LLC (1.29%) and JPMorgan Chase & Co. (0.95%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $1.76.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $296.52 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

The company employs 431 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 3/22/2023 by MarketBeat.com Staff